

# Katy J L Bell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2460213/publications.pdf>

Version: 2024-02-01

110  
papers

2,871  
citations

257450

24  
h-index

223800

46  
g-index

114  
all docs

114  
docs citations

114  
times ranked

4608  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pilot study of an online training program to increase genetic literacy and communication skills in oncology healthcare professionals discussing BRCA1/2 genetic testing with breast and ovarian cancer patients. <i>Familial Cancer</i> , 2022, 21, 157-166.	1.9	9
2	Understanding women's choices for management of cervical intraepithelial neoplasia 2 (CIN2): Qualitative analysis of a randomised experimental study. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2022, 62, 125-132.	1.0	2
3	High value health care is low carbon health care. <i>Medical Journal of Australia</i> , 2022, 216, 67-68.	1.7	25
4	Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF). <i>JAMA Dermatology</i> , 2022, 158, 33.	4.1	26
5	Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis. <i>Cancer Epidemiology</i> , 2022, 77, 102093.	1.9	13
6	Do we need to rethink the diagnoses melanoma <i>in situ</i> and severely dysplastic naevus?. <i>British Journal of Dermatology</i> , 2022, 186, 1030-1032.	1.5	12
7	The impact of health literacy on psychosocial and behavioural outcomes among people at low risk of cardiovascular disease. <i>Preventive Medicine</i> , 2022, 156, 106980.	3.4	3
8	Learning from the pandemic: mortality trends and seasonality of deaths in Australia in 2020. <i>International Journal of Epidemiology</i> , 2022, 51, 718-726.	1.9	10
9	Simulations found within-subject measurement variation in glycaemic measures may cause overdiagnosis of prediabetes and diabetes. <i>Journal of Clinical Epidemiology</i> , 2022, 145, 20-28.	5.0	2
10	What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis. <i>Psycho-Oncology</i> , 2022, 31, 879-892.	2.3	85
11	Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow up? Statistical analysis plan for the MEL-SELF randomised controlled trial. <i>Contemporary Clinical Trials</i> , 2022, , 106761.	1.8	2
12	Evaluation of the Incremental Value of a Coronary Artery Calcium Score Beyond Traditional Cardiovascular Risk Assessment. <i>JAMA Internal Medicine</i> , 2022, 182, 634.	5.1	27
13	Considering potential benefits, as well as harms, from the COVID-19 disruption to cancer screening and other healthcare services. <i>Public Health Research and Practice</i> , 2022, , .	1.5	1
14	A novel methodological framework was described for detecting and quantifying overdiagnosis. <i>Journal of Clinical Epidemiology</i> , 2022, 148, 146-159.	5.0	3
15	Clinician views and experiences of non-invasive prenatal genetic screening tests in Australia. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2022, , .	1.0	2
16	Adenotonsillectomy and adenoidectomy in children: The impact of timing of surgery and post-operative outcomes. <i>Journal of Paediatrics and Child Health</i> , 2022, 58, 1608-1615.	0.8	1
17	Impact of Full-Field Digital Mammography Versus Film-Screen Mammography in Population Screening: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2021, 113, 16-26.	6.3	20
18	Setting minimum clinical performance specifications for tests based on disease prevalence and minimum acceptable positive and negative predictive values: Practical considerations applied to COVID-19 testing. <i>Clinical Biochemistry</i> , 2021, 88, 18-22.	1.9	5

#	ARTICLE	IF	CITATIONS
19	The role of epidemiologists in SARS-CoV-2 and COVID-19 research. <i>Public Health</i> , 2021, 190, e3-e4.	2.9	8
20	COVID-19: estimated number of deaths if Australia had experienced a similar outbreak to England and Wales. <i>Medical Journal of Australia</i> , 2021, 214, 95.	1.7	4
21	How to use imperfect tests for COVID-19 (SARS-CoV-2) to make clinical decisions. <i>Medical Journal of Australia</i> , 2021, 214, 69.	1.7	4
22	Equity and evidence during vaccine rollout: stepped wedge cluster randomised trials could help. <i>BMJ</i> , The, 2021, 372, n435.	6.0	3
23	Guidance for the design and reporting of studies evaluating the clinical performance of tests for present or past SARS-CoV-2 infection. <i>BMJ</i> , The, 2021, 372, n568.	6.0	18
24	A methods review of posttrial follow-up studies of cardiovascular prevention finds potential biases in estimating legacy effects. <i>Journal of Clinical Epidemiology</i> , 2021, 131, 51-58.	5.0	2
25	Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review. <i>PLoS ONE</i> , 2021, 16, e0248946.	2.5	71
26	Overdiagnosis of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. <i>JAMA Network Open</i> , 2021, 4, e215335.	5.9	78
27	Estimating the potential impact of interventions to reduce overcalling and undercalling of melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1519-1527.	2.4	3
28	Active surveillance as a management option for cervical intraepithelial neoplasia 2: An online experimental study. <i>Gynecologic Oncology</i> , 2021, 161, 179-187.	1.4	6
29	Benefits and Harms of Hypertension and High-Normal Labels: A Randomized Experiment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007160.	2.2	9
30	Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial. <i>Trials</i> , 2021, 22, 324.	1.6	10
31	Reply. <i>Journal of Hypertension</i> , 2021, 39, 1045-1046.	0.5	0
32	Evaluation of Gender Inequity in Thyroid Cancer Diagnosis. <i>JAMA Internal Medicine</i> , 2021, 181, 1351.	5.1	87
33	Willingness of blood donors in Australia to provide additional data and blood sample for health research. <i>Transfusion</i> , 2021, 61, 2855-2861.	1.6	6
34	Rethinking Low-Risk Papillary Thyroid Cancers <math>\leq 1\text{cm}</math> (Papillary Microcarcinomas): An Evidence Review for Recalibrating Diagnostic Thresholds and/or Alternative Labels. <i>Thyroid</i> , 2021, 31, 1626-1638.	4.5	4
35	Using marginal structural models to account for selection bias in the analysis of legacy effect. <i>International Journal of Epidemiology</i> , 2021, 50, .	1.9	0
36	Mendelian Randomization in Cardiovascular Research. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e005623.	2.2	9

#	ARTICLE	IF	CITATIONS
37	The potential for overdiagnosis and underdiagnosis because of blood pressure variability: a comparison of the 2017 ACC/AHA, 2018 ESC/ESH and 2019 NICE hypertension guidelines. <i>Journal of Hypertension</i> , 2021, 39, 236-242.	0.5	17
38	Setting analytical performance specifications using HbA1c as a model measurand. <i>Clinica Chimica Acta</i> , 2021, 523, 407-414.	1.1	6
39	Visits to general practitioners after iron-related deferrals from blood donation in middle-aged and older Australian blood donors. <i>Transfusion</i> , 2021, 61, 3335-3343.	1.6	4
40	I need an exact margin measurement for this basal cell carcinoma!. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2021-208030.	2.0	1
41	Causal inference in melanoma epidemiology using Mendelian randomization. <i>British Journal of Dermatology</i> , 2020, 182, 13-14.	1.5	2
42	Test accuracy and potential sources of bias in diagnostic test evaluation. <i>Medical Journal of Australia</i> , 2020, 212, 10.	1.7	6
43	Is the risk of cancer in Australia overstated? The importance of competing mortality for estimating lifetime risk. <i>Medical Journal of Australia</i> , 2020, 212, 17-22.	1.7	8
44	Estimating the magnitude of cancer overdiagnosis in Australia. <i>Medical Journal of Australia</i> , 2020, 212, 163-168.	1.7	92
45	Why clinicians overtest: development of a thematic framework. <i>BMC Health Services Research</i> , 2020, 20, 1011.	2.2	28
46	Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. <i>Jammi</i> , 2020, 5, 223-234.	0.5	339
47	Why We Might Not Need to Stress About Ruling Out Inducible Myocardial Ischemia. <i>Annals of Internal Medicine</i> , 2020, 172, 214.	3.9	0
48	Estimating the magnitude of cancer overdiagnosis in Australia. <i>Medical Journal of Australia</i> , 2020, 213, 189.	1.7	11
49	Mammography screening for breast cancer—the UK Age trial. <i>Lancet Oncology</i> , The, 2020, 21, e504.	10.7	1
50	Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. <i>Cardiovascular Diabetology</i> , 2020, 19, 28.	6.8	31
51	Potential Consequences of Changing Disease Classifications. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 921.	7.4	16
52	The carbon footprint of pathology testing. <i>Medical Journal of Australia</i> , 2020, 212, 377-382.	1.7	68
53	Trends in knee magnetic resonance imaging, arthroscopies and joint replacements in older Australians: still too much low-value care?. <i>ANZ Journal of Surgery</i> , 2020, 90, 833-839.	0.7	17
54	Future directions in cardiovascular disease risk prediction. <i>Australian Journal of General Practice</i> , 2020, 49, 488-494.	0.8	6

#	ARTICLE	IF	CITATIONS
55	Estimated legacy effects from simulated post-trial data were less biased than from combined trial/post-trial data. <i>Journal of Clinical Epidemiology</i> , 2019, 114, 30-37.	5.0	3
56	Rate of normal lung function decline in ageing adults: a systematic review of prospective cohort studies. <i>BMJ Open</i> , 2019, 9, e028150.	1.9	114
57	Socioeconomic disadvantage and cardiovascular risk factors in young Aboriginal and Torres Strait Islander Australians. <i>Medical Journal of Australia</i> , 2019, 211, 259-260.	1.7	1
58	Patients' Views About Skin Self-examination After Treatment for Localized Melanoma. <i>JAMA Dermatology</i> , 2019, 155, 914.	4.1	22
59	Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach. <i>BMJ Open</i> , 2019, 9, e022457.	1.9	24
60	Recognizing the Potential for Overdiagnosis: Are High-Sensitivity Cardiac Troponin Assays an Example?. <i>Annals of Internal Medicine</i> , 2019, 170, 259.	3.9	24
61	Is the NHS 'Heart Age Test' too much medicine?. <i>British Journal of General Practice</i> , 2019, 69, 560-561.	1.4	4
62	Evidence of potential overdiagnosis and overtreatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents: protocol for a scoping review. <i>BMJ Open</i> , 2019, 9, e032327.	1.9	7
63	27...Are we overdiagnosing attention deficit hyperactivity disorder (ADHD)?. , 2019, , .		0
64	Patient Preferences for Follow-up After Recent Excision of a Localized Melanoma. <i>JAMA Dermatology</i> , 2018, 154, 420.	4.1	29
65	Incremental Benefits and Harms of the 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline. <i>JAMA Internal Medicine</i> , 2018, 178, 755.	5.1	40
66	Beyond country-specific incidence and mortality: the global burden of melanoma. <i>British Journal of Dermatology</i> , 2018, 178, 315-316.	1.5	9
67	Patterns and trends of potentially inappropriate high-density lipoprotein cholesterol testing in Australian adults at high risk of cardiovascular disease from 2008 to 2014: analysis of linked individual patient data from the Australian Medicare Benefits Schedule and Pharmaceutical Benefits Scheme. <i>BMJ Open</i> , 2018, 8, e019041.	1.9	5
68	The Importance of Population-Based Estimates of Melanocytic Pathology. <i>JAMA Dermatology</i> , 2018, 154, 15.	4.1	1
69	A stepped wedge cluster randomised trial of nurse-delivered Teach-Back in a consumer telehealth service. <i>PLoS ONE</i> , 2018, 13, e0206473.	2.5	16
70	Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis. <i>BMJ Open</i> , 2018, 8, e020584.	1.9	28
71	Demonstration of Classic Screening Biases, Not Additional Benefit of Annual Over Biennial Screening. <i>Journal of the American College of Radiology</i> , 2018, 15, 1360.	1.8	1
72	Use of shared care and routine tests in follow-up after treatment for localised cutaneous melanoma. <i>BMC Health Services Research</i> , 2018, 18, 477.	2.2	6

#	ARTICLE	IF	CITATIONS
73	Should heart age calculators be used alongside absolute cardiovascular disease risk assessment?. BMC Cardiovascular Disorders, 2018, 18, 19.	1.7	39
74	Prognostic impact of systolic blood pressure variability in people with diabetes. PLoS ONE, 2018, 13, e0194084.	2.5	15
75	Change in Bone Mineral Density Is an Indicator of Treatment-Related Antifracture Effect. Annals of Internal Medicine, 2017, 166, 152.	3.9	0
76	Fear of new or recurrent melanoma after treatment for localised melanoma. Psycho-Oncology, 2017, 26, 1784-1791.	2.3	42
77	Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25Åyears of screening mammography. Breast Cancer Research and Treatment, 2017, 166, 843-854.	2.5	17
78	EARLY CRT MONITORING USING TIME-DOMAIN OPTICAL COHERENCE TOMOGRAPHY DOES NOT ADD TO VISUAL ACUITY FOR PREDICTING VISUAL LOSS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL RANIBIZUMAB. Retina, 2017, 37, 509-514.	1.7	2
79	Systematic review of the effects of care provided with and without diagnostic clinical prediction rules. Diagnostic and Prognostic Research, 2017, 1, 13.	1.8	9
80	General Practitionersâ€™ Decision Making about Primary Prevention of Cardiovascular Disease in Older Adults: A Qualitative Study. PLoS ONE, 2017, 12, e0170228.	2.5	41
81	Whatâ€™s the uptake? Pragmatic RCTs may be used to estimate uptake, and thereby population impact of interventions, but better reporting of trial recruitment processes is needed. BMC Medical Research Methodology, 2017, 17, 174.	3.1	8
82	Prevalence of incidental breast cancer and precursor lesions in autopsy studies: a systematic review and meta-analysis. BMC Cancer, 2017, 17, 808.	2.6	43
83	Assessing the efficacy of cancer screening. Public Health Research and Practice, 2017, 27, .	1.5	10
84	Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data. Journal of Bone and Mineral Research, 2016, 31, 1767-1773.	2.8	24
85	Prevalence of Differentiated Thyroid Cancer in Autopsy Studies Over Six Decades: A Meta-Analysis. Journal of Clinical Oncology, 2016, 34, 3672-3679.	1.6	173
86	Screening tests for gonorrhoea should first do no harm. Medical Journal of Australia, 2015, 202, 281-282.	1.7	3
87	Screening tests for gonorrhoea should first do no harm. Medical Journal of Australia, 2015, 203, 174-174.	1.7	0
88	How Often Do Patients with Localized Melanoma Attend Follow-Up at a Specialist Center?. Annals of Surgical Oncology, 2015, 22, 1164-1171.	1.5	11
89	Prevalence of incidental prostate cancer: A systematic review of autopsy studies. International Journal of Cancer, 2015, 137, 1749-1757.	5.1	293
90	Assessment of changes to screening programmes: why randomisation is important. BMJ, The, 2015, 350, h1566-h1566.	6.0	14

#	ARTICLE	IF	CITATIONS
91	Ambulatory blood pressure adds little to Framingham Risk Score for the primary prevention of cardiovascular disease in older men: secondary analysis of observational study data. <i>BMJ Open</i> , 2014, 4, e006044-e006044.	1.9	9
92	Criteria for monitoring tests were described: validity, responsiveness, detectability of long-term change, and practicality. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 152-159.	5.0	12
93	When to remeasure cardiovascular risk in untreated people at low and intermediate risk: observational study. <i>BMJ</i> , The, 2013, 346, f1895-f1895.	6.0	16
94	Effects of additional blood pressure and lipid measurements on the prediction of cardiovascular risk. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 1474-1485.	1.8	18
95	A Counterargument to Encounter Frequency and Target Achievement: Measurement Variability. <i>Archives of Internal Medicine</i> , 2012, 172, 374.	3.8	0
96	The potential value of monitoring bone turnover markers among women on alendronate. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 195-201.	2.8	21
97	Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. <i>BMJ: British Medical Journal</i> , 2011, 342, d12-d12.	2.3	14
98	Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 4641-4646.	1.6	75
99	The value of routine BMD monitoring after starting bisphosphonate treatment. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 173-174.	2.8	3
100	Should response rules be used to decide continued subsidy of very expensive drugs? A checklist for decision makers. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 99-105.	1.9	4
101	Monitoring Adherence to Medication by Measuring Change in Blood Pressure. <i>Hypertension</i> , 2010, 56, 612-616.	2.7	15
102	Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor-Based Regimens. <i>Hypertension</i> , 2010, 56, 533-539.	2.7	25
103	Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. <i>BMJ: British Medical Journal</i> , 2009, 338, b2266-b2266.	2.3	91
104	Is there a relationship between skin erythema and fatigue in women undergoing irradiation after breast conserving surgery for early breast cancer? A prospective study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 257-263.	1.1	1
105	Thrombin generation as a predictor of radiotherapy induced skin erythema. <i>Radiotherapy and Oncology</i> , 2009, 90, 136-140.	0.6	4
106	Mixed models showed no need for initial response monitoring after starting antihypertensive therapy. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 650-659.	5.0	25
107	Use of randomised trials to decide when to monitor response to new treatment. <i>BMJ: British Medical Journal</i> , 2008, 336, 361-365.	2.3	26
108	Procalcitonin: A Marker of Bacteraemia in SIRS. <i>Anaesthesia and Intensive Care</i> , 2003, 31, 629-636.	0.7	42

#	ARTICLE	IF	CITATIONS
109	Overdiagnosis due to screening mammography for women aged 40 years and over. The Cochrane Library, 0, , .	2.8	4
110	Estimating the Extent of True Asymptomatic COVID-19 and Its Potential for Community Transmission: Systematic Review and Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	68